Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBITDA Margin (2016 - 2025)

Corcept Therapeutics' EBITDA Margin history spans 10 years, with the latest figure at 2.22% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1167.0% year-over-year to 2.22%; the TTM value through Dec 2025 reached 5.88%, down 1440.0%, while the annual FY2025 figure was 5.88%, 1440.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 2.22% at Corcept Therapeutics, down from 4.92% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 32.09% in Q4 2021 and bottomed at 2.17% in Q1 2025.
  • The 5-year median for EBITDA Margin is 23.26% (2023), against an average of 21.04%.
  • The largest annual shift saw EBITDA Margin soared 685bps in 2021 before it plummeted -2061bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 32.09% in 2021, then plummeted by -32bps to 21.83% in 2022, then grew by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then plummeted by -84bps to 2.22% in 2025.
  • Per Business Quant, the three most recent readings for CORT's EBITDA Margin are 2.22% (Q4 2025), 4.92% (Q3 2025), and 13.72% (Q2 2025).